BRAF and hepatocellular carcinoma: As expected, the growth of the two EGFR-mutated cell lines was also inhibited at lower doses (HCC-827: IC50, 0.06 μM; SE, 0.005; PC-9: IC50, 0.04 μM; SE, 0.004), whereas no effect on the growth of the BRAF class 1–mutated cell line (HCC-364: IC50, >25 μM) and the KRAS-mutated cell line (ADK-17: IC50, >25) was observed (Fig 3C; Appendix Table A1).